Triglycerides and triglyceride-rich lipoproteins in cardiovascular disease: a current view Hermes Toros Xavier

Abstract

It is essential to understand the role of LRTG in atherosclerotic burden; their structural characteristics, such as lipid content, apolipoproteins, particle size, and time of removal from circulation, are decisive. More specific methods that can quantify LRTG, define all subclasses, and the various metabolic pathways that give rise to them are necessary to clarify which types of LRTG are involved in the progression of atherosclerosis, in addition to clarifying the mechanisms of action and defining potential therapeutic targets capable of modulating TG metabolism and their interactions. It must be recognized that the drugs currently recommended to reduce TG, such as fibrates and omega-3 FA, present contradictory or even futile results in reducing the risk of CVD, whether in monotherapy or in combination with statins. The determining reasons will need to be better clarified in the future. And finally, that lifestyle changes, including reducing carbohydrate intake, alcohol intake, body weight and smoking, are the main measures for controlling TG, positively impacting CV risk.